Profil Penggunaan Granulocyte Colony Stimulating Factor (G-Csf) Pada Pasien Kanker Dengan Neutropenia di RSUP Dr. Kariadi Semarang

Abstract

The incidence of neutropenia in cancer patients is 90% caused to chemotherapy. Delays in treating neutropenia can increase the risk of febrile neutropenia, which can lead to high mortality. Cancer patients with neutropenia can be given granulocyte colony-stimulating factor (G-CSF) therapy, which can reduce the incidence of febrile neutropenia, and length of stay, and reduce the morbidity and mortality in cancer patients. The purpose of this study was to determine the profile of G-CSF use in cancer patients with neutropenia. The G-CSF used was Filgrastrim and Lenograstrim. This study used a Retrospective Cohort Study with observational analytics at RSUP Dr. Kariadi Semarang. Research data were collected retrospectively using medical records in the 2019-2022 period. The research sample obtained 56 subjects who met the inclusion criteria. Based on research results, cancer patients with neutropenia are more common in non-hematological cancer patients (62.5%) with the most common age range being 18-60 years (78.6%). The highest grade of neutropenia experienced by patients was severe neutropenia (55.3%), while moderate neutropenia was (32.2%), and mild neutropenia was (12.5%). Profile of the use of G-CSF in cancer patients with neutropenia at Dr. The Kariadi studied were Filgrastrim and Lenograstrim. Some patients were given Filgrastrim (73.2%) and those who were given Lenograstrim were some (26.8%).